Last reviewed · How we verify
NCT01747642
Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma
Phase 2/Phase 3 trial testing Oncoxin in Quality of Life in 60 participants. Status unknown.
1 December 2013
Quick facts
| Lead sponsor | Clinical Research Organization, Dhaka, Bangladesh |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 December 2012 |
| Primary completion | 1 December 2013 |
| Estimated completion | 1 June 2014 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Oncoxin
- Suranix — full drug profile →
Conditions studied
- Quality of Life — all drugs for Quality of Life →
Sponsor
Clinical Research Organization, Dhaka, Bangladesh
Who can join
Adults 18 to 70, any sex, with Quality of Life. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Number of patients who have prolonged survival
Time frame: 24 weeks
To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks
Sponsor's own description
Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01747642
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Quality of Life
Currently open trials in the same condition.
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT07416448 — Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting
- NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07280416 — Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01747642 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Research Organization, Dhaka, Bangladesh
- Last refreshed: 11 December 2012
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01747642.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing